StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck U.S. Share of Capital Expenditures by Year

U.S. Share of Capital Expenditures (%) (%)

Merck U.S. Share of Capital Expenditures: 2.5% in FY2025, up 0.1 pts from a year earlier.

Latest, FY2025
2.5%
Period ended Dec 31, 2025
Change on a year earlier
+0.1 pts
2.4% in FY2024
History
7 years
Since FY2019
Sources
5
Documents cited below

Where the FY2025 figure comes from

“Capital expenditures were $4.1 billion in 2025, $3.4 billion in 2024 and $3.9 billion in 2023. Expenditures in the U.S. were $2.5 billion in 2025, $2.4 billion in 2024 and $2.5 billion in 2023.”

Source: Form 10-K (mrk-20251231.htm, filed 2026-02-24) ↗

Reported in Form 10-K MD&A Capital Expenditures.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedU.S. Share of Capital Expenditures (%) (%)Year on yearSource
FY2025Dec 31, 20252.5%+0.1 ptsForm 10-K (mrk-20251231.htm, filed 2026-02-24) ↗
FY2024Dec 31, 20242.4%-0.1 ptsForm 10-K (mrk-20251231.htm, filed 2026-02-24) ↗
FY2023Dec 31, 20232.5%-0.2 ptsForm 10-K (mrk-20251231.htm, filed 2026-02-24) ↗
FY2022Dec 31, 20222.7%-0.1 ptsForm 10-K (mrk-20241231.htm, filed 2025-02-25) ↗
FY2021Dec 31, 20212.8%+0.2 ptsForm 10-K (mrk-20231231.htm, filed 2024-02-26) ↗
FY2020Dec 31, 20202.6%+0.7 ptsForm 10-K (mrk-20221231.htm, filed 2023-02-24) ↗
FY2019Dec 31, 20191.9%–Form 10-K (mrk-20211231.htm, filed 2022-02-25) ↗

Cite this data

StockData. (2026). Merck U.S. Share of Capital Expenditures (%), annual FY2019–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/capex-us-share-pct

See every metric in the Merck KPI table. Data updated Oct 26, 2026.